Eli Lilly and Company will participate in the Morgan Stanley 24th Annual Global Healthcare Conference on September 14, 2026. Ilya Yuffa, Lilly's executive vice president and president of Lilly USA and Global Customer Capabilities, will join a fireside chat at 1:50 p.m. Eastern time. The event will be webcast live and available for replay on Lilly's investor website. This participation highlights Lilly's ongoing commitment to advancing healthcare innovations and communicating with investors about their progress in treating major health challenges like diabetes, obesity, Alzheimer's, immune disorders, and cancer.
Viking Therapeutics surged 26.5% after releasing positive topline results from its GLP-1/GIP agonist VK2735 maintenance dosing study in adults with obesity. The data suggest multiple effective maintenance dosing schedules, potentially improving patie...
Ken Langone, co-founder of Home Depot, stated that Eli Lilly stock could reach $2,000 within the next 3 to 4 years, challenging the long-term success of his Home Depot investment. Eli Lilly has shown strong growth, up over 54% in the past year despit...
Eli Lilly reported a strong quarter beating revenue and earnings estimates, driven by its dominant GLP-1 obesity and diabetes drugs Mounjaro and Zepbound. Despite this, the stock fell 7.2% over the past month due to pricing pressures and competition....
Since Medicare began covering obesity drugs in July, 700,000 new seniors have started GLP-1 treatments, with 70% using Eli Lilly's medicines. The coverage, part of a temporary "Bridge" program, allows eligible seniors to access weight loss drugs for ...
Eli Lilly reported a remarkable 48% revenue growth driven by strong sales of Mounjaro and Zepbound, yet its stock price remains nearly flat this year. Despite recent stock volatility due to price cuts, acquisition charges, and competition concerns, a...
